Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
Cancer
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...
HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...
Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer
China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...
Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...
Chipscreen’s Epidaza Patent Faces Invalidation Request Review
China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...
Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series
US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)...
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
Menarini Group Expands Oncology Pipeline with Insilico Medicine License
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...
Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer
China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...
Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...
MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26
US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received...